This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Open-Label Tiagabine Monotherapy for Major Depressive Disorder With Anxiety

Linda L. Carpenter, MD; Jordan M. Schecter, MD; Audrey R. Tyrka, MD, PhD; Andrea F. Mello, MD; Marcelo F. Mello, MD; Ryan Haggarty, MA; and Lawrence H. Price, MD

Published: January 16, 2006

Article Abstract

Objective: Gamma-aminobutyric acid (GABA) plays a key role in the pathophysiology and treatment of depression and anxiety. Tiagabine, a selective GABA reuptake inhibitor (SGRI) that enhances normal GABA tone, was evaluated for its efficacy and safety in the treatment of depression comorbid with significant anxiety.

Method: In this 8-week, single-center, open-label study, adults with DSM-IV-diagnosed major depressive disorder and significant anxiety (i.e., “anxious depression”) received tiagabine monotherapy, initiated at 4 mg/day and titrated for optimum response as tolerated to a maximum dose of 20 mg/day. Symptoms, function, and adverse events were assessed at regular intervals. Patients were entered from April 2002 to February 2003.

Results: Nineteen patients entered the study and 15 met criteria for intent-to-treat analyses. Of those, 6 (40%) discontinued treatment and 9 (60%) completed the 8-week protocol. Tiagabine significantly improved depression, as shown by a reduction in mean ± SD Hamilton Rating Scale for Depression scores from baseline (31.9 ± 6.1) to endpoint (17.0 ± 12.4; p = .002). Categorical response rate was 47% (N = 7). Tiagabine also significantly improved anxiety (Hamilton Rating Scale for Anxiety baseline score of 22.7 ± 4.9 vs. endpoint score of 12.5 ± 8.8; p=.002). The mean±SD final daily dose was 12.8 ± 5.8 mg. The most commonly reported adverse events were dizziness, headache, and gastrointestinal upset/nausea.

Conclusion: These results suggest the potential of the SGRI tiagabine in the treatment of depression with anxiety. Large, placebo-controlled trials are needed.

Volume: 67

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...